HJF Research Funding Newsletter
October's Featured Opportunities
- Complex Geometries for Extended Wear Respirators Towards Regenerable Particulate Matter Protection
- Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials
- Integrated Deployable Microsensors for Chemical Detection
- Far Forward Manufacturing of CBRN Sensors
- OPEN TOPIC – Tactical Chem Bio Visualization (Human-Machine Interface)
- Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics
- OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)
- Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)
Novel Technologies for CWMD and Related Threats - Open Topic
Unbiased Behavioral Discovery Platforms: The DoW seeks to develop unguided behavioral discovery technologies to accelerate detection and medical countermeasure development against current and future threats. These platforms will enable 1) Quantification of novel behaviors in pre-clinical animal models that are more sensitive than state-of-the-art, and 2) High-throughput evaluation of intervention efficacy in animal models with high translational value.
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
The National Institute of General Medical Sciences (NIGMS) Biomedical Technology Optimization and Dissemination Centers (BTOD) program supports optimization of late-stage technologies that have demonstrated laboratory feasibility. The centers will move the technologies to the point where they can be widely used and will promote their dissemination within the biomedical research community. NIGMS intends to reissue a Notice of Funding Opportunity to continue to support the BTOD Centers program.
Due October 8, 2025: RFI- Broad Spectrum Prophylactics for Acetylcholinesterase Inhibitors
DTRA JSTO's Enabling Science and Technology Division (RD-CBE) has released a draft Statement of Objective (SOO) seeking to develop JEDAI, an Enterprise Data and DevSecOps-enabled AI/ML Ecosystem for the Chemical and Biological Defense Program (CBDP)
The ARPA-H description is a repeat from the section above it. It should read as: Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE)